Skip to content
Screener

Neuronetics STIM Q2 2026 earnings

Reported August 11, 2026 · Before market open

Revenue$41.6MBeat by $1.4M
EPS-$0.05Beat by $0.07
Revenue estimate$40.2M
EPS estimate-$0.12
“This was a quarter of real operational progress, and meaningful steps toward our goal of sustained profitability and positive net cash flow from operations and investing. For some time, NeuroStar has not competed to its full potential, and we are changing that by broadening how customers can access our technology while we continue to drive operational gains across the Greenbrook clinics. We also strengthened our leadership team, adding proven talent in key roles. The combination of a leading TMS platform and a national care network is what sets Neuronetics apart, and it positions us to lead as new interventional therapies come to market. There is more work ahead, but I am encouraged by the traction we are beginning to demonstrate.”
Dan Reuvers

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$40.4M
EPS estimate-$0.08

Financials

Q2 2026

Income statement

See full
Revenue$41.6M+9.1%
Gross profit$21.2M+19.5%
Operating income-$1.5M+81.4%
Net income-$3.4M+66.0%
EPS (diluted)-$0.05+66.7%

Balance sheet

See full
Cash & equivalents$19.2M+75.0%
Total debt$86.5M+7.3%
Total equity$17.9M-34.2%
Total assets$131.5M-2.3%

Cash flow

See full
Operating cash flow-$1.0M+71.2%
CapEx$417.0K+65.5%
Free cash flow-$1.4M+62.1%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$213.35M+11.6%
Enterprise value$280.68M+7.5%
P/S1.4×-0.3×

Profitability

See full
Gross margin49.1%-7.0pp
Operating margin-14.7%-5.4pp
Net margin-19.6%-7.0pp
FCF margin-7.7%-3.3pp

Returns & leverage

See full
Return on equity-135.3%-35.4pp
Debt / equity4.8×+1.9×
Current ratio1.9×-0.1×

Segments

By segment

See full
Greenbrook$26.9M—
Neurostar$14.7M—

By geography

See full
Non Us$1.0M+100%

By product

See full
Service$26.9M—

FAQ

When did Neuronetics report Q2 2026 earnings?
Neuronetics (STIM) reported Q2 2026 earnings on August 11, 2026 before market open.
What were Neuronetics's Q2 2026 revenue and EPS?
Neuronetics reported revenue of $41.6M and eps of $-0.05 for Q2 2026.
Did Neuronetics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $40.2M by $1.4M. EPS beat the consensus estimate of $-0.12 by $0.07.
How did Neuronetics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 9.1% from $38.1M a year earlier and eps grew 66.7% from $-0.15.
Where can I find Neuronetics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-343474) and the 10-Q periodic report (0001104659-26-094078) directly on SEC EDGAR. The filing index links above go to sec.gov.